BrightSpring Healthの空売り状況は、投資家がBrightSpring Healthの株価下落に賭けている度合いを知ることができます。空売りデータは2週間ごとに更新されます。

BrightSpring Health (NASDAQ:BTSG) 株価情報, 空売り情報

BrightSpring Health

BrightSpring Health Services Inc is a home and community-based healthcare services platform, focused on delivering complementary pharmacy and provider services to complex patients. Its platform delivers clinical services and pharmacy solutions across Medicare, Medicaid, and commercially insured populations. Its segments include Pharmacy Solutions, Provider Service. and others. It generates the majority of its revenue from the Pharmacy Solutions segment.

BrightSpring Health Services, Inc. - Common Stock

BrightSpring Health Services Inc

BrightSpring Health Services, Inc. - Tangible Equity Unit

BTS GROUP HLDGS UNSP/ADR by BTS Group Holdings Public Company Ltd

BTS Group Holdings PLC

Transaction Eliminates More Than $20 Million in Debt, and Other Financial Obligations, Provides $2 million in Cash and Significantly Enhances the Company's Balance Sheet and Liquidity
The Company will review with shareholders at 2:00 p.m. EST, details below.
GARDEN CITY, NY, Jan. 22, 2025 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRPH#NASDAQ">PRPH</a>) ("ProPhase" or the "Company"), a next-generation biotech, genomics, and diagnostics company, today announced the closing of the sale of its wholly-owned subsidiaries, Pharmaloz Manufacturing Inc. and Pharmaloz Real Estate Holdings, Inc. (collectively "Pharmaloz" or "PMI"), to a private equity group based in Houston, Texas ("Buyer" or "Buyers"). The transaction carries an aggregate deal value of approximately $23.6 million and will immediately bolster ProPhase's balance sheet and liquidity by eliminating over $20 million in debt, payables, and other contingent liabilities.
As part of this transformative deal, the Buyers are providing approximately $2 million in cash payments while more than $10 million in debt will be retired. Additionally, the Buyers are assuming nearly $2 million in capital leases and close to $3 million in current and accrued payables, as well as canceling $300,000 in accrued interest tied to the debt being retired. The private equity firm will further assume approximately $3 million of upcoming capital expenditures.
The transaction includes the acquisition of Pharmaloz Real Estate Holdings, with the private equity group assuming the existing $3.3 million mortgage on PMI's manufacturing facility. Several ProPhase employees will transfer to Pharmaloz, thereby reducing the Company's overhead. Overall, the transaction better positions the Company to focus on its highly promising and high value core businesses.

News

Asset Sales

PRPH

ProPhase Labs Announces $23.6M Sale Of Pharmaloz Units To Houston Equity Group, Eliminates $20M Debt, Gains $2M Cash

WIIM

Amphenol shares are trading higher after the company reported better-than-expected Q4 financial results and issued Q1 2025 guidance above estimates.

Evercore ISI Group analyst Jonathan Chappell maintains United Parcel Service (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UPS#NYSE">UPS</a>) with a In-Line and raises the price target from $141 to $147.

Price Target

Analyst Ratings

Evercore ISI Group Maintains In-Line on United Parcel Service, Raises Price Target to $147

Hepion Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HEPA#NASDAQ">HEPA</a>), a clinical stage biopharmaceutical company that has been developing a treatment for non-alcoholic steatohepatitis ("NASH"), hepatocellular carcinoma ("HCC"), and other chronic liver diseases, announced the launch of a "best efforts" public offering of 27,692,310 shares of common stock (or pre-funded warrants in lieu thereof) with each share of common stock (or pre-funded warrant) accompanied by (i) a series A common warrant to purchase one (1) common share at an exercise price of $0.40 per share and (ii) a series B common warrant to purchase one (1) common share at an exercise price of $0.40 per share. The combined offering price of each share of common stock together with the accompanying series A and series B common warrants is $0.325, and the combined offering price of each pre-funded warrant together with the accompanying series A and series B common warrants is $0.3249. The gross proceeds of the public offering are expected to be approximately $9.0 million before deducting placement agent fees and offering expenses and are expected to be used to repay certain indebtedness and for general corporate purposes, including working capital, operating expenses and capital expenditures. The closing of the public offering is expected to occur on or about January 23, 2025, subject to the satisfaction of customary closing conditions.
Laidlaw &amp; Company (UK) Ltd. is acting as the sole placement agent for the offering.

Offerings

HEPA

Hepion Pharmaceuticals Announces $9M Public Offering

Biotech

General

RIGL

Rigel Enrolls First Patient In Phase 1 Study Evaluating Fostamatinib In Sickle Cell Disease

New Partnership Gives Customers In-the-Moment Access to a Wide Array of Home Improvement Essentials
<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.doordash.com%2F&amp;esheet=54186123&amp;newsitemid=20250122137273&amp;lan=en-US&amp;anchor=DoorDash&amp;index=1&amp;md5=152b3364a77827c21d10ff5bf49d4a8c">DoorDash</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DASH#NASDAQ">DASH</a>) today announced a new partnership with <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.homedepot.com%2F&amp;esheet=54186123&amp;newsitemid=20250122137273&amp;lan=en-US&amp;anchor=The+Home+Depot&amp;index=2&amp;md5=42b14840d1b9eb1e52e595f5f1b936af">The Home Depot</a> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HD#NYSE">HD</a>). The world's largest home improvement retailer with over 2,000 stores nationwide is now available for on-demand delivery with DoorDash. This partnership brings home improvement essentials to both the doorstep and work site in as little as an hour.&#x2A;

DASH

DoorDash Partners With The Home Depot For 1-Hour Delivery Of Home Improvement Essentials

Deutsche Bank analyst Brian Bedell maintains Charles Schwab (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SCHW#NYSE">SCHW</a>) with a Buy and raises the price target from $98 to $105.

SCHW

Deutsche Bank Maintains Buy on Charles Schwab, Raises Price Target to $105

Rosenblatt analyst Mike Genovese maintains Adtran Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADTN#NASDAQ">ADTN</a>) with a Buy and raises the price target from $10 to $15.

ADTN

Rosenblatt Maintains Buy on Adtran Holdings, Raises Price Target to $15

U.S. stock futures were higher this morning, with the Nasdaq futures gaining over 150 points on Wednesday.
Shares of Progress Software Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRGS#NASDAQ">PRGS</a>) fell sharply in today's pre-market trading after the company issued first-quarter EPS <a href="https://www.benzinga.com/quote/PRGS/earnings">guidance below estimates</a>.
Progress Software reported quarterly earnings of $1.33 per share which beat the analyst consensus estimate of $1.22 per share. The company reported quarterly sales of $215.00 million which beat the analyst consensus estimate of $211.25 million.
Progress Software said it sees first-quarter revenue of $232 million to $238 million versus market estimates of $235.840 million. The company projects adjusted earnings of $1.02 to $1.08 per share, versus expectations of $1.25 per share.
Progress Software shares declined 2.6% to $61.90 in the pre-market trading session.
Here are some other stocks moving lower in pre-market trading.
<ul>
<li>Associated Capital Group, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AC#NYSE">AC</a>) fell 43.7% to $20.00 in pre-market trading. Associated Capital recently reported estimated fourth quarter and full year results</li>
<li>Septerna, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SEPN#NASDAQ">SEPN</a>) fell 14.4% to $16.01 in pre-market trading after gaining more than 10% on Tuesday.</li>
<li>AnaptysBio, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANAB#NASDAQ">ANAB</a>) declined 12.3% to $14.81 in pre-market trading after gaining over 6% on Tuesday.</li>
<li>Marine Products Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MPX#NYSE">MPX</a>) dipped 11.3% to $8.04 in pre-market trading. Marine Products will release its financial results for the fourth quarter on Thursday, Jan. 30, before the market opens.</li>
<li>Zenas BioPharma, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZBIO#NASDAQ">ZBIO</a>) shares fell 8.2% to $7.71 in pre-market trading.</li>
<li>GH Research PLC (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GHRS#NASDAQ">GHRS</a>) dipped 7.7% to $8.30 in pre-market trading.</li>
<li>Dogness (International) Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DOGZ#NASDAQ">DOGZ</a>) fell 4.5% to $27.47 in pre-market trading.</li>
<li>Disc Medicine, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IRON#NASDAQ">IRON</a>) fell 2.7% to $58.88 in pre-market trading as the company announced a proposed $200 million public offering of common stock and pre-funded warrants.</li>
</ul>
Now Read This:
<ul>
<li> <a href="https://www.benzinga.com/25/01/43096091/jim-cramer-this-tech-stock-is-a-buy-louisiana-pacific-has-been-a-great-stock">Jim Cramer: This Tech Stock Is A Buy, Louisiana-Pacific Has Been A &#8216;Great Stock&#8217;</a></li>
</ul>

Pre-Market Outlook

Markets

Movers

Trading Ideas

ANAB

DOGZ

GHRS

IRON

PRGS

SEPN

ZBIO

Progress Software, Disc Medicine And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session

Guidance

MDAI

Spectral AI Updated Operating Results, Pending The Completion Of Its Audited Financial Statements, The Company Anticipates Reporting Annual Revenue Exceeding Its $28M Market Guidance

<h3>Gainers</h3>
<table>
<thead>
<tr>
<th>Symbol</th>
<th>Name</th>
<th align="right">Price</th>
<th align="right">Change ($)</th>
<th align="right">Change (%)</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLK#NYSE">XLK</a>)</td>
<td>SPDR Select Sector Fund - Technology</td>
<td align="right">239.0900</td>
<td align="right">3.030</td>
<td align="right">1.28</td>
<td>39.9K</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLP#NYSE">XLP</a>)</td>
<td>SPDR Select Sector Fund - Consumer Staples</td>
<td align="right">78.1040</td>
<td align="right">0.504</td>
<td align="right">0.64</td>
<td>17.1K</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLU#NYSE">XLU</a>)</td>
<td>SPDR Select Sector Fund - Utilities</td>
<td align="right">80.1100</td>
<td align="right">0.060</td>
<td align="right">0.07</td>
<td>9.0K</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLV#NYSE">XLV</a>)</td>
<td>SPDR Select Sector Fund - Health Care</td>
<td align="right">142.5285</td>
<td align="right">0.029</td>
<td align="right">0.02</td>
<td>10.1K</td>
</tr>
</tbody>
</table>
<h3>Losers</h3>
<table>
<thead>
<tr>
<th>Symbol</th>
<th>Name</th>
<th align="right">Price</th>
<th align="right">Change ($)</th>
<th align="right">Change (%)</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLE#NYSE">XLE</a>)</td>
<td>SPDR Select Sector Fund - Energy Select Sector</td>
<td align="right">93.07</td>
<td align="right">-0.41</td>
<td align="right">-0.44</td>
<td>14.6K</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLY#NYSE">XLY</a>)</td>
<td>SPDR Select Sector Fund - Consumer Discretionary</td>
<td align="right">230.44</td>
<td align="right">-0.46</td>
<td align="right">-0.20</td>
<td>1.0K</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLRE#NYSE">XLRE</a>)</td>
<td>Real Estate Select Sector SPDR Fund (The)</td>
<td align="right">41.77</td>
<td align="right">-0.06</td>
<td align="right">-0.15</td>
<td>1.0K</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLF#NYSE">XLF</a>)</td>
<td>SPDR Select Sector Fund - Financial</td>
<td align="right">50.58</td>
<td align="right">-0.07</td>
<td align="right">-0.14</td>
<td>179.3K</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLI#NYSE">XLI</a>)</td>
<td>SPDR Select Sector Fund - Industrial</td>
<td align="right">140.52</td>
<td align="right">-0.06</td>
<td align="right">-0.05</td>
<td>4.4K</td>
</tr>
</tbody>
</table>
<a href="https://pro.benzinga.com/?utm_source=insights">Pulled from Benzinga Pro data</a> this sector movers alerts can help traders understand macro-level market trends. Traders often look for sector movers to provide high-level analysis on which sectors are over- or under-performing to make better investing decisions on exchange traded funds (ETFs) or individual tickers in those sectors. 
To read more about sector movers, <a href="https://www.benzinga.com/movers">click here</a>.

Sector ETFs

ETFs

XLRE

Select Sector SPDR-Consumer Discretionary

Leading And Lagging Sectors For January 22, 2025

KIDS

OrthoPediatrics Corp.'s OPSB Division Establishes Distribution Agreement With Thrive Orthopedics

<ul>
<li>Mr. Shantharam is a proven biotech industry executive with over two decades of senior leadership experience in finance, commercial and corporate operations</li>
<li>Dr. Klencke is a seasoned clinical leader in oncology drug development with more than 20 years of industry experience</li>
<li>Dr. Takimoto brings a distinguished track record in oncology and drug development with 17 years of industry experience &nbsp;</li>
</ul>
SOUTH SAN FRANCISCO, Calif., Jan. 22, 2025 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., ("ALX Oncology" or the "Company") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALXO#NASDAQ">ALXO</a>), a clinical-stage biotechnology company advancing therapies that boost the immune system to treat cancer and extend patients' lives, today announced the appointment of Harish Shantharam, CFA, as Chief Financial Officer (CFO). In addition, the company appointed Barbara Klencke, M.D., and Chris H. Takimoto, M.D., Ph.D., FACP, to its Board of Directors. These appointments follow the recent additions to the ALX Oncology executive team of Alan Sandler, M.D., as Chief Medical Officer, and Allison Dillon, Ph.D., as Chief Business Officer.

Management

ALXO

ALX Oncology Announced New Appointments: Harish Shantharam as CFO, Dr. Barbara Klencke and Dr. Chris H. Takimoto to Board of Directors

Seagate Technology Holdings plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STX#NASDAQ">STX</a>) reported better-than-expected second-quarter <a href="https://www.benzinga.com/quote/STX/earnings">earnings on Tuesday</a>.
The company posted quarterly earnings of $2.03 per share which beat the analyst consensus estimate of $1.88 per share. The company reported quarterly sales of $2.33 billion which beat the analyst consensus estimate of $2.32 billion.
&#8220;Seagate ended calendar 2024 on a strong note as we grew revenue, gross margin and non-GAAP EPS successively in each quarter of the year. Our results demonstrate structural improvements in the business and our focus on value capture in an improving demand environment, highlighted by decade-high gross margin performance exiting the December quarter,&#8221; said Dave Mosley, Seagate&#8217;s chief executive officer.
Seagate shares gained 3.7% to close at $101.25 on Tuesday.
These analysts made changes to their price targets on Seagate following earnings announcement.
<ul>
<li>Morgan Stanley analyst Erik Woodring maintained Seagate with an Overweight rating and raised the price target from $129 to $134.</li>
<li>Barclays analyst Tom O&#8217;Malley maintained the stock with an Equal-Weight rating and raised the price target from $95 to $105.</li>
<li>Northland Capital Markets analyst Gus Richard reiterated Seagate with an Outperform rating and raised the price target from $144 to $160.</li>
</ul>
Considering buying STX stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="606" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/22074329/image-152-1024x606.png" alt="" class="wp-image-744626" style="width:498px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/22074329/image-152-1024x606.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/22074329/image-152-300x178.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/22074329/image-152-768x455.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/22074329/image-152.png 1111w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/25/01/43123084/top-3-health-care-stocks-that-could-blast-off-this-quarter">Top 3 Health Care Stocks That Could Blast Off This Quarter</a></li>
</ul>

Earnings

These Analysts Increase Their Forecasts On Seagate After Strong Q2 Earnings

B of A Securities analyst Jason Kupferberg maintains Visa (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/V#NYSE">V</a>) with a Neutral and raises the price target from $314 to $331.

B of A Securities Maintains Neutral on Visa, Raises Price Target to $331

President Donald Trump signed an executive order on January 20, 2025, initiating the United States&#8217; withdrawal from the World Health Organization (WHO).
The <a target="_blank" href="https://www.whitehouse.gov/presidential-actions/2025/01/withdrawing-the-united-states-from-the-worldhealth-organization/" rel="noreferrer noopener">move</a> marks a continuance of Trump&#8217;s first-term efforts to end WHO membership, citing concerns about the organization&#8217;s governance and financial practices. Former President Joe Biden reversed Trump&#8217;s initial withdrawal attempt upon taking office in 2021.
In his order, Trump pointed to the WHO&#8217;s handling of the COVID-19 pandemic, its alleged susceptibility to political influence, and a lack of meaningful reforms as primary reasons for the decision.
The U.S. has criticized the organization&#8217;s funding structure, emphasizing that American contributions far outweigh those of other nations. For example, China, with a population over three times that of the U.S., contributes approximately 90% less to the WHO&#8217;s budget, the executive order says.
The executive order formally <a target="_blank" href="https://www.nytimes.com/2025/01/20/us/politics/trump-world-health-organization.html" rel="noreferrer noopener">revokes</a> the 2021 Presidential Letter that retracted the U.S.&#8217;s initial notification to withdraw. Trump&#8217;s administration argued that WHO has failed to demonstrate independence from undue political influence and continues to impose unfair financial demands on the U.S.
The WHO said it <a target="_blank" href="https://www.who.int/news/item/21-01-2025-who-comments-on-united-states--announcement-of-intent-to-withdraw" rel="noreferrer noopener">regretted</a> the decision, emphasizing the historic partnership between the organization and the United States. As a founding member since 1948, the U.S. has played a significant role in shaping the WHO&#8217;s initiatives and policies.
The collaboration has led to major public health achievements, including the eradication of smallpox and the near-eradication of polio. WHO highlighted that American institutions have contributed to and benefited from the partnership over the past seven decades.
The U.S. decides to withdraw when global health challenges require coordinated efforts. While the WHO faces criticism, the organization argues that U.S. involvement has been critical to protecting Americans and addressing international health crises.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/large-cap/25/01/43122667/oracle-unveils-ai-powered-sales-tools-to-boost-customer-engagements-details" target="_blank" rel="noreferrer noopener">Oracle Unveils AI-Powered Sales Tools To Boost Customer Engagements: Details</a></li>
</ul>
Image via Shutterstock

Government

Regulations

Health Care

BMED

Harvard Apparatus Regenerative Technology

HART

iShares Dow Jones US Health Care Provides Index Fund

iShares Trust S&P Global Healthcare Sector Index Fund

iShares Trust Dow Jones US Healthcare Sector Index Fund

PINK

World Health Organization Responds to Trump's Order, Reminds Decades of Successful Health Achievements

<a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4345249-1&amp;h=3899264366&amp;u=https%3A%2F%2Fwww.leidos.com%2F&amp;a=Leidos">Leidos</a> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LDOS#NYSE">LDOS</a>) today announced a new prime contract to provide Key Management Architecture &amp; Engineering and Cyber Security Engineering Support Services to the Department of Defense, Intelligence Community and civilian agencies. The contract was awarded by the Naval Information Warfare Center Pacific and has a one-year base period of performance and four one-year optional extensions. The contract has a total value of $120 million if all options are exercised.

Contracts

LDOS

Leidos Wins $120M Cybersecurity And Cryptographic Key Management Contract

Rosenblatt analyst Kevin Cassidy maintains Seagate Tech Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STX#NASDAQ">STX</a>) with a Buy and raises the price target from $140 to $150.

Rosenblatt Maintains Buy on Seagate Tech Hldgs, Raises Price Target to $150

<ul>
<li>Phase II trial evaluating efti in combination with radiotherapy plus KEYTRUDA&#xAE; (pembrolizumab) in patients with soft tissue sarcoma reaches enrolment target of 40 patients</li>
<li>Data updates from EFTISARC-NEO expected in 2025</li>
</ul>
SYDNEY, AUSTRALIA, Jan. 22, 2025 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=Myt3eFY_s-NgDjNrKHaBtrTo_PDtFWd-sjW_IN3hrWQkZfwDUMn3zLJBILeI-3EL8QvJIZY7bAxmYzcgUrH2RA==">Immutep Limited</a> ((ASX: IMM, NASDAQ:<a href="https://www.benzinga.com/stock/IMMP#NASDAQ">IMMP</a>) ("Immutep" or "the Company"), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disease, today announces that patient enrolment has been completed in the investigator-initiated EFTISARC-NEO trial. EFTISARC-NEO is evaluating eftilagimod alpha (efti) in combination with radiotherapy plus KEYTRUDA&#xAE; (pembrolizumab) in the neoadjuvant setting for patients with resectable soft tissue sarcoma (STS).
The Phase II trial conducted by the Maria Skłodowska-Curie National Research Institute of Oncology (MSCNRIO) in Warsaw, the national reference centre for STS in Poland, has reached its enrolment target of 40 patients.
As previously announced, positive data from EFTISARC-NEO was presented at the Connective Tissue Oncology Society (CTOS) Annual Meeting in November 2024. Among 21 patients available for primary endpoint assessment, the triple combination achieved a greater than three-fold increase in tumour hyalinization/fibrosis (median 50%) at the time of surgical resection as compared to a historical median 15% from radiotherapy alone. This is an early surrogate endpoint at the time of surgery as tumour hyalinization/fibrosis has been associated with improved survival for STS patients.1,2
Additionally, the treatment has been safe with no grade ≥3 toxicities related to efti and pembrolizumab.
Data updates from EFTISARC-NEO are expected in 2025. For more information on the trial, please visit clinicaltrials.gov (NCT06128863).

IMMP

Immutep Completes Enrolment Of 40 Patients In Phase II EFTISARC-NEO Trial Evaluating Efti With Radiotherapy And KEYTRUDA For Soft Tissue Sarcoma; Data Updates Expected In 2025; Achieved A Three-Fold Increase In Tumour Hyalinization/Fibrosis; No Grade ≥3 Toxicities Reported

URGN

UroGen Highlights Results From Study On Durability Of Response From Post-Commercialization Of JELMYTO Titled 'Durability of Response of UGN-101: Longitudinal Follow-Up of Multicenter Study'

Morgan Stanley analyst Erin Wright maintained a Buy rating on BrightSpring Health Services, Inc. (BTSG – Research Report) today and set a price tar...

Morgan Stanley Sticks to Its Buy Rating for BrightSpring Health Services, Inc. (BTSG)

Morgan Stanley analyst Erin Wright raised the firm's price target on BrightSpring Health (BTSG) to $20 from $19 and keeps an Overweight rating on t...

BrightSpring Health price target raised to $20 from $19 at Morgan Stanley

Mizuho raised the firm's price target on BrightSpring Health (BTSG) to $22 from $20 and keeps an Outperform rating on the shares in conjunction wit...

BrightSpring Health price target raised to $22 from $20 at Mizuho

Reports preliminary adjusted EBITDA of approximately $588M. Sees FY25 revenue of $11.5B-$12B, consensus $12.39B. Sees FY25 adjusted EBITDA of $540M...

BrightSpring reports preliminary FY24 revenue $11.2B-$11.3B, consensus $11.17B

BrightSpring Health (BTSG) announced it has entered into a definitive agreement to divest its Community Living business, namely ResCare Community L...

BrightSpring Health to divest Community Living business

BrightSpring divests community living business for $835M; raises FY24 revenue outlook

The latest update is out from BrightSpring Health Services, Inc. ( ($BTSG) ). On January 17, 2025, BrightSpring Health Services, through its subsid...

BrightSpring Health Divests Community Living to Sevita

Mizuho Securities analyst Ann Hynes has maintained their bullish stance on BTSG stock, giving a Buy rating on January 20. Ann Hynes has given her B...

BrightSpring Health Services, Inc. Receives Buy Rating from Ann Hynes Amid Strategic Divestiture and Positive Financial Outlook

Whit Mayo, an analyst from Leerink Partners, reiterated the Buy rating on BrightSpring Health Services, Inc. (BTSG – Research Report). The associat...

BrightSpring Health Services, Inc.: Strategic Divestiture Fuels Strong Buy Rating and Growth Outlook

BTIG analyst David Larsen maintained a Buy rating on BrightSpring Health Services, Inc. (BTSG – Research Report) today and set a price target of $2...

BTIG Keeps Their Buy Rating on BrightSpring Health Services, Inc. (BTSG)

BTSG

Press Releases

HAVEN HOSPICE ACQUIRED BY BRIGHTSPRING HEALTH SERVICES

Financing

KKR to Purchase of 11,619,998 Shares of BrightSpring Health Services Common Stock from Walgreens Boots Alliance

BrightSpring Health Services, Inc. Welcomes Dr. Steve Miller to Board of Directors

BrightSpring Health Services, Inc. to Announce Third Quarter 2024 Financial Results on November 1, 2024

BrightSpring Health Services, Inc. Reports Third Quarter 2024 Financial Results and Increases Full Year 2024 Guidance

BrightSpring Health Services Announces CareMed Was Selected as a National Specialty Pharmacy Partner for Leqembi®

BrightSpring Health Services, Inc. to Participate in Two Upcoming Investor Conferences

BrightSpring Health Services Announces Onco360® Has Been Selected as a Partner for Several New Drugs

BrightSpring Health Services, Inc. Announced Refinancing of Term Loan B

BrightSpring Health Services, Inc. Enters into Definitive Agreement to Divest Community Living Business to Sevita; Reports Preliminary 2024 Financial Results and Provides 2025 Guidance Excluding Community Living

Addus HomeCare Corporation - Common Stock

Addus HomeCare

Agilon Health

Amedisys

AMN Healthcare Services

Astrana Health

Chemed

Cigna

CorVel

CVS Health

Quest Diagnostics Incorporated Common Stock

Quest Diagnostics

DaVita

Fresenius Medical Care AG American Depositary Shares (Each representing 1/2 of an Ordinary Share)

Comments

BrightSpring Health

空売り

BrightSpring Health (NASDAQ:BTSG) 株価情報, 空売り情報

こんな人も見ています

ニュース

パートナーシップ

ベンジンガ・グローバル